Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair. READ MORE
Improving provider response to adverse events through an algorithm.
Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair.
In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors are more effective and safer than conventional second-line treatment
Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year.
A systemic immune response, rather than a local response of a tumor, determines successful remission following cancer immunotherapy.
Research in Review
Human epidermal growth factor receptor 2-targeted therapy results in different objective response rates across cancer types based on mutation variants.
A recent clinical trial of a CAR T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive NHL independent of disease type, stage, or characteristics.
A targeting agent is more effective in improving progression-free survival and overall survival than conventional therapy in older patients with a treatment-naïve B-cell malignancy.
Scientists said on Monday they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.